The company's capital structure is heavily burdened by a $113.9M accumulated deficit, leaving shareholders exposed to significant value destruction despite a current ratio of 3.25.
| Total Current Assets | 5.91M | 7.35M | 1.05M | 1.75M | 3.94M | 2.18M | 224.75K | 505 | 153.56K | 383 |
| Cash & Short-Term Investments | 5.26M | 6.35M | 532.88K | 1.47M | 3.79M | 2.18M | 202.97K | 505 | 153.56K | 383 |
| Cash Only | 5.21M | 5.67M | 532.88K | 1.47M | 3.79M | 2.18M | 202.97K | 505 | 153.56K | 383 |
| Short-Term Investments | 50.55K | 676.6K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 15.29K | 7.35K | 0 | 38.98K | 8.07K | 0 | 21.79K | 0 | 0 | 0 |
| Days Sales Outstanding | 8.95 | 1.97 | - | - | - | - | 258.51 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 631.08K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Assets | 13.88M | 12.49M | 7.86M | 6.32M | 3.97M | 4.59M | 75.73K | 171.04K | 0 | 46.54K |
| Property, Plant & Equipment | 89.25K | 18.4K | 59.78K | 108.88K | 71.46K | 31.85K | 73.73K | 0 | 0 | 0 |
| Fixed Asset Turnover | 28.78x | 74.08x | - | - | - | 2.35x | 0.42x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 316.09K | 361.25K | 541.88K | 2.55M | 3.55M | 0 | 0 | 0 | 0 | 46.54K |
| Long-Term Investments | 37M | 7.86M | 5.69M | 3.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 313.89K | 4.25M | 1.56M | 158.33K | 348.33K | 4.55M | 2K | 171.04K | 0 | 0 |
| Total Assets | 19.79M | 19.84M | 8.91M | 8.07M | 7.92M | 6.77M | 300.48K | 171.54K | 153.56K | 46.92K |
| Asset Turnover | 0.08x | 0.07x | - | - | - | 0.01x | 0.10x | - | - | - |
| Asset Growth % | 255.36% | 122.71% | 10.38% | 1.96% | 17% | 2151.56% | 75.16% | 11.71% | 227.27% | - |
| Total Current Liabilities | 1.82M | 1.77M | 4.51M | 2.99M | 2.17M | 2.76M | 5.28M | 155.85K | 705.22K | 310.94K |
| Accounts Payable | 1.01M | 888.75K | 1.27M | 1.42M | 99.02K | 134.09K | 1.62M | 450 | 55.22K | 215.94K |
| Days Payables Outstanding | 1.88K | 1.8K | - | - | - | - | 614.7 | - | - | - |
| Short-Term Debt | 100K | 118.88K | 1.19M | 1.01M | 1.89M | 2.42M | 1.88M | 152.64K | 650K | 95K |
| Deferred Revenue (Current) | 2.72M | 599.46K | 0 | 0 | 0 | 0 | 1M | 2.76K | 0 | 0 |
| Other Current Liabilities | 1.23M | 161.05K | 1.28M | 555.95K | 182K | 0 | 0 | 0 | 0 | 0 |
| Current Ratio | 3.25x | 4.16x | 0.23x | 0.59x | 1.81x | 0.79x | 0.04x | 0.00x | 0.22x | 0.00x |
| Quick Ratio | 3.25x | 4.16x | 0.23x | 0.59x | 1.81x | 0.79x | 0.04x | 0.00x | 0.22x | 0.00x |
| Cash Conversion Cycle | -1.87K | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 317.63K | 528.13K | 768.43K | 1.29M | 1.65M | 164.72K | 0 | 0 | 0 |
| Long-Term Debt | 0 | 150K | 150K | 150K | 150K | 1.65M | 150K | 0 | 0 | 0 |
| Capital Lease Obligations | 18.87K | 0 | 18.88K | 61.18K | 14.72K | 0 | 14.72K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 167.63K | 359.25K | 557.25K | 1.13M | 0 | -1 | 0 | 0 | 0 |
| Total Liabilities | 390.53K | 2.09M | 5.04M | 3.76M | 3.46M | 4.41M | 5.44M | 155.85K | 705.22K | 310.94K |
| Total Debt | 100K | 268.88K | 1.4M | 1.22M | 2.06M | 4.08M | 2.09M | 152.64K | 650K | 95K |
| Net Debt | -5.11M | -5.41M | 866.17K | -244.91K | -1.73M | 1.9M | 1.88M | 152.14K | 496.44K | 94.62K |
| Debt / Equity | 0.01x | 0.02x | 0.36x | 0.28x | 0.46x | 1.74x | - | 9.73x | - | - |
| Debt / EBITDA | -0.01x | - | - | - | - | - | - | 0.89x | - | 0.04x |
| Net Debt / EBITDA | 0.44x | - | - | - | - | - | - | 0.89x | - | 0.04x |
| Interest Coverage | -20.90x | -18.11x | -26.29x | -196.49x | -171.03x | -70.87x | -60.79x | - | - | - |
| Total Equity | 17.58M | 17.75M | 3.87M | 4.31M | 4.45M | 2.35M | -5.14M | 15.69K | -551.66K | -264.01K |
| Equity Growth % | 653.71% | 359.11% | -10.36% | -3.13% | 89.45% | 145.7% | -32876.84% | 102.84% | -108.95% | - |
| Book Value per Share | 2.91 | 4.19 | 2.01 | 0.17 | 0.31 | 2.30 | -0.25 | 0.00 | -296.11 | -141.71 |
| Total Shareholders' Equity | 17.18M | 17.25M | 3.19M | 4.31M | 4.45M | 2.35M | -5.14M | 15.69K | -551.66K | -264.01K |
| Common Stock | 656 | 575 | 212 | 3.53K | 1.96K | 3.55K | 2.52K | 25K | 1.6K | 3.76K |
| Retained Earnings | -113.87M | -109.95M | -98.23M | -87.36M | -66.09M | -27.55M | -14.1M | -9.31K | -3.33M | -2.93M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | -247.16K | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 401.88K | 506.16K | 682.06K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Insufficient cash runway
As reported in recent financial statements, Coeptis Therapeutics has seen its total assets fluctuate significantly, reaching $19.8M in 2026Q1, yet this growth is largely offset by a persistent accumulation of retained earnings deficits that now exceed $113.9M, signaling a precarious long-term financial trajectory.
The company's asset base appears to be driven more by periodic financing events than by organic value creation from its clinical pipeline. Investors should monitor whether the current asset level can support the necessary R&D intensity required to reach meaningful clinical milestones without further dilutive capital raises.
Based on 2026Q1 filings, the company maintains a current ratio of 3.25, which appears superficially healthy but masks a cash position of only $5.2M that remains highly susceptible to rapid depletion given the firm's ongoing, high-burn clinical development activities.
While the current ratio has improved from the sub-1.0 levels observed in 2024, this improvement appears to be a function of recent financing rather than operational cash generation. The lack of a sustainable revenue stream suggests that this liquidity buffer may be insufficient to cover the next phase of clinical trials.
According to historical balance sheet data, the company's equity base of $17.2M as of 2026Q1 is heavily burdened by a massive accumulated deficit, which suggests that shareholders have absorbed significant value destruction to fund the company's pre-commercial research and development efforts.
The reliance on equity financing to sustain operations implies that existing shareholders face a high risk of further dilution. The persistent negative retained earnings indicate that the company has yet to achieve a return on invested capital, making the equity value highly speculative.
As indicated by quarterly balance sheet disclosures, the presence of goodwill and intangible assets, which totaled $316.1K in 2026Q1, warrants further investigation as these items may be subject to impairment if the company's clinical programs fail to meet their projected regulatory or commercial milestones.
The valuation of these intangible assets appears to be based on optimistic assumptions regarding the success of the GEAR platform and other pipeline assets. Any failure to advance these programs could lead to non-cash write-downs that would further erode the company's already strained equity position.
Quick answers to the most common questions about buying COEPW stock.
As of 2025, Coeptis Therapeutics Holdings, Inc. (COEPW) had total assets of $19.8M including $7.4M in current assets.
Coeptis Therapeutics Holdings, Inc. (COEPW) carries total debt of $0.3M, offset by $6.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Coeptis Therapeutics Holdings, Inc. (COEPW) has total shareholders' equity (book value) of $17.2M ($4.19 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Coeptis Therapeutics Holdings, Inc. (COEPW) reported a current ratio of 4.16x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.